Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Academic Article


  • The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease. Copyright © 2014 by the National Comprehensive Cancer Network. All rights reserved.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Coit DG; Thompson JA; Andtbacka R; Anker CJ; Bichakjian CK; Carson WE; Daniels GA; Daud A; DiMaio D; Fleming MD
  • Start Page

  • 621
  • End Page

  • 629
  • Volume

  • 12
  • Issue

  • 5